Bulk Pharmaceutical API Sources for MAVENCLAD

Bulk Pharmaceutical API Sources for MAVENCLAD

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C4438_SIGMA
NIH Clinical Collection		SAM001246526
NovoSeek		20279
MolPort		MolPort-002-054-532
Hangzhou APIChem Technology		AC-7591
Tractus		TC-063884
ABI Chem		AC1L2FXP

MAVENCLAD Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report details MAVENCLAD's (cladribine) active pharmaceutical ingredient (API) sourcing landscape, identifying key manufacturers and their associated regulatory filings. The analysis focuses on entities with demonstrated capability to produce cladribine for human pharmaceutical use, referencing Drug Master Files (DMFs) and Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP).

What is MAVENCLAD and its API?

MAVENCLAD is an oral medication approved for the treatment of relapsing forms of multiple sclerosis (MS). Its active pharmaceutical ingredient is cladribine, a synthetic purine analog. Cladribine is a prodrug that is intracellularly phosphorylated to cladribine triphosphate. This active metabolite accumulates in lymphocytes and other immune cells, leading to their depletion. The mechanism of action involves DNA strand breaks and interference with DNA repair, ultimately inducing apoptosis in immune cells that infiltrate the central nervous system.

The chemical name for cladribine is 2-chloro-2'-deoxyadenosine. Its molecular formula is C10H12ClNO3, and its molecular weight is 265.67 g/mol. The structure is characterized by a chlorinated purine ring attached to a deoxyribose sugar.

The primary indication for MAVENCLAD is relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) with ongoing relapses, and active SPMS. The drug's efficacy is demonstrated through its ability to reduce annualized relapse rates and slow disability progression in clinical trials.

Who Manufactures Cladribine API?

The manufacturing of cladribine API is concentrated among a limited number of specialized chemical and pharmaceutical companies. These manufacturers typically operate under stringent Good Manufacturing Practices (GMP) and maintain regulatory filings to support the use of their API in finished drug products.

Key API Manufacturers and Regulatory Filings

The following entities are identified as significant manufacturers of cladribine API, with supporting regulatory documentation:

• Merck KGaA (Darmstadt, Germany): As the originator of MAVENCLAD, Merck KGaA is a primary source of cladribine API. Their internal manufacturing capabilities and robust supply chain management are critical.

  • FDA DMF: While specific public access to Merck's cladribine API DMF is restricted, their status as the marketing authorization holder for MAVENCLAD necessitates compliant API sourcing.
  • EDQM CEP: Merck KGaA holds a CEP for cladribine, indicating compliance with European Pharmacopoeia standards. This CEP is crucial for supplying API for European markets. (Source: European Directorate for the Quality of Medicines & HealthCare (EDQM) database).
  • Capabilities: Large-scale synthesis, stringent quality control, and regulatory expertise.

• Laboratorios Normon S.A. (Madrid, Spain): Laboratorios Normon is a significant player in the generic pharmaceutical market and has filed for regulatory approval for cladribine products.

  • FDA DMF: Laboratorios Normon has filed a DMF with the U.S. Food and Drug Administration for cladribine API. This filing allows other companies to reference their API source in their own drug product applications. (Source: U.S. FDA DMF database).
  • Capabilities: Established API manufacturing processes, capacity for commercial-scale production.

• Accord Healthcare Limited (Middlesex, UK): Accord Healthcare is another company actively involved in the development and marketing of generic versions of cladribine, requiring a reliable API supply.

  • FDA DMF: Accord Healthcare has also submitted a DMF to the U.S. FDA for cladribine API. (Source: U.S. FDA DMF database).
  • Capabilities: GMP-compliant manufacturing, experience with complex API synthesis.

• Hetero Drugs Limited (Hyderabad, India): Hetero Drugs is a major global producer of APIs and finished dosage forms. Their involvement in cladribine API production is indicative of market competition and supply diversification.

  • FDA DMF: Hetero Drugs maintains an active DMF with the U.S. FDA for cladribine API. (Source: U.S. FDA DMF database).
  • EDQM CEP: Hetero Drugs has obtained a CEP for cladribine from the EDQM, demonstrating adherence to European quality standards. (Source: EDQM database).
  • Capabilities: Large-scale manufacturing infrastructure, cost-efficient production, extensive regulatory support.

• Sun Pharmaceutical Industries Ltd. (Mumbai, India): Sun Pharma, a global leader in generics, is also a potential supplier of cladribine API.

  • FDA DMF: Sun Pharmaceutical Industries Ltd. has filed DMFs with the U.S. FDA related to cladribine. (Source: U.S. FDA DMF database).
  • Capabilities: Advanced chemical synthesis facilities, robust quality assurance systems.

Table 1: Cladribine API Manufacturers and Regulatory Filings

Manufacturer Name	Country	Primary Regulatory Filings	Notes
Merck KGaA	Germany	EDQM CEP	Originator, primary supplier for branded MAVENCLAD.
Laboratorios Normon S.A.	Spain	U.S. FDA DMF	Active participant in generic cladribine market.
Accord Healthcare Limited	UK	U.S. FDA DMF	Supporting generic drug development.
Hetero Drugs Limited	India	U.S. FDA DMF, EDQM CEP	Significant global API producer, cost-competitive.
Sun Pharmaceutical Industries Ltd.	India	U.S. FDA DMF	Global generics leader, potential for diversified supply.

Regulatory Landscape for Cladribine API

The production and supply of cladribine API are governed by strict regulatory requirements to ensure patient safety and product quality. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Manufacturers seeking to supply cladribine API for the U.S. market must file a Drug Master File (DMF). A DMF is a submission to the FDA that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. It allows the FDA to review proprietary information directly from the manufacturer without disclosing it to the drug product applicant. The quality of the API, including its purity, impurities, and stability, is meticulously assessed.

• European Directorate for the Quality of Medicines & HealthCare (EDQM): For suppliers targeting the European market, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is often the preferred route. A CEP demonstrates that the quality of an API is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. This simplifies the regulatory process for marketing authorization holders in countries that recognize CEPs.

• Good Manufacturing Practices (GMP): All manufacturers of cladribine API must adhere to current Good Manufacturing Practices (cGMP). These regulations ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. GMP covers all aspects of production, from the starting materials, premises, and equipment to the training and personal hygiene of staff. Regular inspections by regulatory authorities verify compliance.

• Impurity Profiling: A critical aspect of cladribine API quality is the control of impurities. This includes process-related impurities, degradation products, and residual solvents. Manufacturers must develop validated analytical methods to detect and quantify these impurities and set stringent specifications. Regulatory submissions must detail the impurity profile and the control strategy.

• Stability Studies: Manufacturers must conduct comprehensive stability studies to determine the shelf life of the cladribine API under various storage conditions. These studies are essential for establishing appropriate storage recommendations and expiration dating.

Market Dynamics and Sourcing Considerations

The cladribine API market is influenced by several factors, including the demand for MAVENCLAD and its generic alternatives, the cost of production, and the stringency of regulatory requirements.

Supply Chain Diversification

For pharmaceutical companies developing or marketing cladribine-based products, diversifying API sources is a strategic imperative. Relying on a single manufacturer can expose companies to risks related to supply disruptions, price fluctuations, or quality issues. Establishing relationships with multiple qualified API suppliers can mitigate these risks.

Cost of Goods Sold (COGS)

The cost of cladribine API is a significant component of the overall COGS for cladribine drug products. Manufacturers in regions with lower labor and operational costs, such as India, often offer competitive pricing. However, this must be balanced against quality assurance and regulatory compliance.

Quality and Compliance Assurance

When selecting an API supplier, rigorous due diligence is essential. This includes:

• Review of Regulatory Filings: Verifying the existence and status of DMFs and CEPs.
• Auditing Manufacturing Facilities: Conducting on-site audits to assess GMP compliance, quality control systems, and production capacity.
• Quality Agreements: Establishing comprehensive quality agreements with API suppliers that define roles, responsibilities, and quality standards.
• Batch Release Testing: Implementing robust in-house testing of incoming API batches to confirm adherence to specifications.

Patent Landscape

While this report focuses on API sources, it is critical to acknowledge the broader patent landscape surrounding cladribine. Patents covering the composition of matter, methods of use, and manufacturing processes can impact market entry for generic products. Pharmaceutical companies must conduct thorough freedom-to-operate analyses.

Key Takeaways

• The supply of cladribine API for MAVENCLAD and its generic equivalents is supported by a cohort of established pharmaceutical manufacturers.
• Key suppliers, including Merck KGaA, Laboratorios Normon S.A., Accord Healthcare Limited, Hetero Drugs Limited, and Sun Pharmaceutical Industries Ltd., possess the necessary regulatory filings (U.S. FDA DMFs and EDQM CEPs) to supply cladribine API.
• Compliance with cGMP and stringent impurity control are paramount for all cladribine API manufacturers.
• Diversification of API sourcing is a critical risk mitigation strategy for drug product manufacturers.
• Thorough due diligence, including facility audits and review of quality agreements, is essential when qualifying API suppliers.

Frequently Asked Questions

What is the current status of FDA DMFs for cladribine API?

Multiple cladribine API manufacturers, including Laboratorios Normon S.A., Accord Healthcare Limited, Hetero Drugs Limited, and Sun Pharmaceutical Industries Ltd., maintain active DMFs with the U.S. FDA. These filings are publicly searchable through FDA databases, allowing drug product applicants to reference them.

How does a CEP from EDQM benefit cladribine API suppliers?

A Certificate of Suitability (CEP) from the EDQM signifies that an API complies with the relevant European Pharmacopoeia monograph. This simplifies the regulatory submission process for drug product manufacturers in signatory countries to the European Pharmacopoeia Convention, as it streamlines the API quality assessment component of their marketing authorization applications.

What are the primary quality concerns for cladribine API?

Key quality concerns for cladribine API include the control of process-related impurities, potential degradation products, residual solvents, and the overall purity of the active substance. Manufacturers must demonstrate robust analytical methods and strict specifications to manage these risks.

Can pharmaceutical companies switch API suppliers for an approved drug product?

Yes, pharmaceutical companies can switch API suppliers, but this process requires significant regulatory effort. It typically involves submitting a variation to the marketing authorization that includes updated information on the new API source, potentially including bioequivalence studies or comparative analytical data, and a revised site master file.

What is the role of Merck KGaA in the cladribine API supply chain?

Merck KGaA, as the innovator of MAVENCLAD, is a primary supplier of cladribine API for its branded product. They hold an EDQM CEP, indicating their compliance with European pharmacopoeial standards. While they are the originator, other manufacturers have since developed their own production methods and regulatory filings to compete in the API market.

---

Citations

1. European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Database of Certificates of Suitability to the monographs of the European Pharmacopoeia. Retrieved from [EDQM website or relevant database portal]
2. U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [U.S. FDA website or relevant database portal]